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sinus node or the blood supply to the sinus
node. The interventional incision will not
act as a substrate for atrial arrhythmias
because there is no atrial tissue surrounding
the incision around which a tachycardia
circuit could propagate; the incision is an-
chored on either end by the nonconducting
boundaries of the atriotomy and the right
atrioventricular annulus. In fact, treatment
of atrial arrhythmias by the Fontan revision
surgeries with the right atrial maze proce-
dures are designed create conduction block
by similar but more extensive means.5
I agree that early postoperative sinus
node dysfunction is associated with the de-
velopment of late sinus node dysfunction
and late atrial tachyarrhythmias. In our
clinical trial, we reported a high percentage
of early sinus node dysfunction in both the
control and intervention groups, with no
statistically significant difference between
the two groups. Thus the sinus node dys-
function seen in this study was not attrib-
utable to the interventional atrial incision.
Our study reported only the short-term
outcomes of our interventional atrial inci-
sion for the prevention of intra-atrial reen-
trant tachycardia in the lateral tunnel Fon-
tan population. We have learned that, in
contrast to previous clinical and animal
studies, inducible perioperative atrial ar-
rhythmias were not especially common
clinically in these patients. Following up
our cohort to assess long-term arrhythmia
prevalence will provide a useful addition to
our knowledge of the arrhythmia substrate
in the Fontan population.
Kathryn K. Collins, MD
University of California, San Francisco
521 Parnassus, C-346, Box 0632
San Francisco, CA 94117
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Ventral cardiac denervation: Is it
truly an effective prophylaxis against
atrial fibrillation after coronary
artery bypass grafting?
To the Editor:
We read with interest the article by Melo
and colleagues1 on ventral cardiac dener-
vation (VCD) as a prophylaxis against
atrial fibrillation (AF) after coronary revas-
cularization. However, we wish to point
out certain aspects of the methodology that
may have affected the results. Post-CABG
AF is paroxysmal in a large proportion of
patients and does not always give rise to
clinical symptoms. The fact that only 34%
and 33% of the patients in their VCD and
control groups, respectively, had continu-
ous telemetry monitoring for 4 days would
have significantly reduced the AF detection
rate, the primary end point of the study.
Although statistically nonsignificant, the
mixture of different myocardial preserva-
tion strategies used (crystalloid cardiople-
gia, blood cardioplegia, and off-pump) ef-
fectively reduced the advantage of the large
number of patients in the study.
We conducted a study between January
2002 and April 2003 (Table 1) in which we
compared the incidence of AF among 70
consecutive patients undergoing primary
CABG with that among 70 consecutive pa-
tients who underwent VCD (with the same
technique described by Melo and col-
leagues1) in addition to primary CABG.
All patients were operated by the same
consultant surgeon with the same bypass
method and myocardial preservation tech-
nique (antegrade-retrograde cold St
Thomas’ Hospital blood cardioplegia). All
patients had continuous telemetry monitor-
ing for 5 days after the operation. In con-
TABLE 1. Data and outcome after ventral cardiac denervation in patients un-
dergoing CABG with or without VCD
Preoperative variables
VCD
(n  70)
No VCD
(n  70) P value
Age (y, mean  SD) 65 10 65 9 .7
Sex (M/F) 5:1 6:1 .6
Disease severity (%) .8
Single vessel 1% 3%
Double vessel 23% 22%
Triple vessel 76% 75%
Left ventricular function (%) .5
50% 76% 80%
50%–30% 17% 16%
 30% 7% 4%
Myocardial infarction (%) .8
Never 69% 71%
30 d 28% 25%
1–30 d 3% 4%
Diabetes 16% 13% .6
Hypertension (%) 65% 57% .4
Chronic obstructive airway disease (%) 10% 11% .8
Parsonnet score (mean  SD) 7.1 5.5 6.8 6.5 .9
EuroSCORE (mean  SD) 2.5 1.7 2.3 1.7 .6
-Blockers (%) 69% 72% .4
Crossclamp time (min, mean  SD) 34.3 7.5 33.4 7.5 .6
Bypass time (min, mean  SD) 57 13.5 54 12.2 .1
No. of grafts (mean  SD) 2.8 2.9 .9
Postoperative inotropes (%) 13% 8% .4
Reoperation (%) 1.4% 1.4% .999
Total blood loss (mL, mean  SD) 603 299 648 412 .6
Length of stay (d, mean  SD) 7 0.8 7.5 1.2 .8
AF (%) 29% 34% .3
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trast to the findings of Melo and col-
leagues,1 and despite the younger age of
our patients, we found no significant dif-
ference in the incidence of AF between the
two well-matched groups in our study.
Melo and colleagues1 failed to come up
with a convincing reason for the claimed
effectiveness of the technique. Anatomi-
cally, the route taken by autonomic nerves
to the heart is highly variable2; a lesser but
significant and variable proportion of auto-
nomic nerves reaches the heart along the
pulmonary veins and the back of the heart,
so the actual denervation achieved in quan-
titative terms is not consistent or compara-
ble between patients unless the innervation
is mapped out before denervation. The in-
clusion of patients with diabetes (26% in
the VCD group and 27% in the control
group in their study and 16% and 13%,
respectively, in our own study) and patients
receiving -blockers (75% in the VCD
group and 81% in the control group in their
study and 69% and 72%, respectively, in
our study) gives rise to additional prob-
lems. Many patients with diabetes already
have partial denervation from preexisting
autonomic neuropathy, and it is debatable
how much additional denervation is
achieved surgically with the technique.
-Blockers themselves have antiarrhyth-
mic effects and produce a state of near-total
pharmacologic sympathetic denervation.
Long-term -blockade causes -receptor
hypersensitivity, necessitating reintroduc-
tion of -blockers after the operation. The
reintroduction of -blockers in most cases
in the postoperative period results in total
cardiac sympathetic denervation and partial
parasympathetic denervation, which raises
questions about the whole hypothesis.
One can only meaningfully assess the
effectiveness of the technique through a
prospective, randomized multicenter trial
excluding patients with diabetes and those
receiving -blockers. Histologic quantifi-
cation of the amount and type of nerve
fibrils in the excised fat pads is also neces-
sary.
Joseph Alex, MBBS, MRCS
Mazhar Ur Rehman, MBBS, FRCS (CTh)
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Use of enoxaparin in cardiac surgery
To the Editor:
We congratulate Dr Medalion and cowork-
ers1 for the results reported in their study
recently published in the Journal that fo-
cused on the effects of enoxaparin in pa-
tients undergoing coronary operations. The
optimal administration of low-molecular-
weight heparin in cardiac surgery is a con-
troversial issue.2,3 The use of enoxaparin in
patients with prosthetic valves has also
been recently described.4,5 Because we
have routinely used enoxaparin both pre-
operatively and postoperatively in non-
emergency cardiac patients at our institu-
tion during the last 5 years, we would like
to outline some aspects of our experience.
When we started using enoxaparin in
1998, we had some concerns related to the
potential bleeding hazards. Although we
never measured anti-factor Xa activity, we
did not experience any major bleeding
complications that could primarily be re-
lated to the use of enoxaparin itself, and we
gradually developed a simplified protocol
(Table 1), which is, however, significantly
different from the one described. Doses of
preoperative enoxaparin are much lower,
and antiplatelet therapy is stopped on ad-
mission. On the other hand, a low dose of
enoxaparin is given to all patients awaiting
surgical intervention once daily (twice
daily if the dose exceeds 4000 U/d). Also,
patients who could potentially be stabilized
with higher doses of enoxaparin and treated
on an urgent basis, typically patients with
coexistent left main disease and unstable
angina, are instead treated as emergency
cases and, as such, receive unfractionated
heparin infusion until transfer to the oper-
ating room. Enoxaparin is also used after
surgical intervention to minimize thrombo-
embolic complications until a satisfactory
international normalized ratio is attained in
patients receiving oral anticoagulation and
to prevent deep venous thrombosis.
In the study cited above,1 although it is
clear that patients classified as emergency
cases receive heparin infusion, the authors
do not specify when to administer subcu-
taneous enoxaparin versus intravenous
heparin in urgent cases. The level of anti-
coagulation and the laboratory tests used
(eg, partial thromboplastin time and acti-
vated clotting time) in patients receiving
intravenous heparin are also not reported,
and this might influence the measurements
of anti-factor Xa activity at skin incision.
Although results might be biased by a spe-
cial accuracy in surgical hemostasis in pa-
tients enrolled in the study, bleeding rates
were low in all subgroups despite high
doses of enoxaparin (1 mg/kg twice daily),
TABLE 1. Use of enoxaparin before and after cardiac operations
Variable Dose
Preoperative course
Standard minimal dose 2000 U
Minimal dose in patients with atrial fibrillation or
oral anticoagulation
4000 U
Maximal dose 2  4000 U
Conditions that modify preoperative doses
Intravenous nitrates or left main stenosis 50% 2  dose
Endocarditis or cardiac neoplasm 2  dose
Body mass index 30 2  dose
Body mass index 25 1/2 dose
Ticlopidine or clopidogrel withdrawal 1/2 dose
Hemoglobin 12 g/dL 1/2 dose
Postoperative course
Standard dose 2000 U until mobilization
Oral anticoagulation or atrial fibrillation 4000 U until INR 2
Body mass index 30 4000 U until mobilization
One hundred units of enoxaparin  1 mg.
INR, International normalized ratio.
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